Proteon Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch PRTO and buy or sell other stocks, ETFs, and their options commission-free!

About PRTO

Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. 

CEO
Timothy P. Noyes, MBA
CEOTimothy P. Noyes, MBA
Employees
51
Employees51
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2001
Founded2001
Employees
51
Employees51

PRTO Key Statistics

Market cap
1.54B
Market cap1.54B
Price-Earnings ratio
-3.94
Price-Earnings ratio-3.94
Dividend yield
Dividend yield
Average volume
1.04M
Average volume1.04M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$7.82
52 Week high$7.82
52 Week low
$2.77
52 Week low$2.77

Stock Snapshot

Proteon Therapeutics(PRTO) stock is priced at $28.69, giving the company a market capitalization of 1.54B. It carries a P/E multiple of -3.94.

On 2026-03-16, Proteon Therapeutics(PRTO) stock opened at —, reached a high of —, and a low of —.

The Proteon Therapeutics(PRTO)'s current trading volume is 0, compared to an average daily volume of 1.04M.

During the past year, Proteon Therapeutics(PRTO) stock moved between $2.77 at its lowest and $7.82 at its peak.

During the past year, Proteon Therapeutics(PRTO) stock moved between $2.77 at its lowest and $7.82 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.